

CLINICAL CANCER RESEARCH

TABLE OF CONTENTS

HIGHLIGHTS

4169 Selected Articles from This Issue

SPECIAL FEATURES

CCR Translations

4171 **PD-1 Blockade in Chinese versus Western Patients with Melanoma**
Alexander N. Shoushtari, Riyue Bao, and Jason J. Luke
See related article, p. 4250

4174 **Differentiating the Differentiation Syndrome Associated with IDH Inhibitors in AML**
Joshua F. Zeidner
See related article, p. 4280

4177 **TCR Repertoire Changes during TIL Expansion: Clonal Selection or Drifting?**
Maria Lozano-Rabella and Alena Gros
See related article, p. 4289

CCR Drug Updates

4180 **FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer**
Suparna Wedam, Lola Fashoyin-Aje, Xin Gao, Erik Bloomquist, Shenghui Tang, Rajeshwari Sridhara, Kirsten B. Goldberg, Bellinda L. King-Kallimanis, Marc R. Theoret, Amna Ibrahim, Laleh Amiri-Kordestani, Richard Pazdur, and Julia A. Beaver

Review

4186 **PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice**
Iñaki Eguren-Santamaria, Miguel F. Sanmamed, Sarah B. Goldberg, Harriet M. Kluger, Miguel A. Idoate, Benjamin Y. Lu, Jesús Corral, Kurt A. Schalper, Roy S. Herbst, and Ignacio Gil-Bazo

Perspectives

4198 **The World of Clinical Trial Development Post COVID-19: Lessons Learned from a Global Pandemic**
Fatima Karzai, Ravi A. Madan, and William L. Dahut

4201 **Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era**
Michele Maio, Omid Hamid, James Larkin, Alessia Covre, Maresa Altomonte, Luana Calabrò, Santosh A. Vardhana, Caroline Robert, Ramy Ibrahim, Andrea Anichini, Jedd D. Wolchok, and Anna Maria Di Giacomo

CLINICAL TRIALS: TARGETED THERAPY

4206 **EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression**
Stephanie Lheureux, Ana Oaknin, Swati Garg, Jeffrey P. Bruce, Ainhua Madariaga, Neesha C. Dhani, Valerie Bowering, Justin White, Sarah Accardi, Qian Tan, Marsela Braunstein, Katherine Karakasis, Iulia Cirlan, Stephanie Pedersen, Tiantian Li, Lorena Fariñas-Madrid, Yeh Chen Lee, Zhihui (Amy) Liu, Trevor J. Pugh, and Amit M. Oza

4216 **Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase**
AC Yuqin Song, Keshu Zhou, Dehui Zou, Jianfeng Zhou, Jianda Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Haiyi Guo, Lei Zhou, Rebecca Elstrom, Jane Huang, William Novotny, Rachel Wei, and Jun Zhu

4225 **A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma**
Sant P. Chawla, Sanjay Goel, Warren Chow, Fadi Braiteh, Arun S. Singh, Juneko E. Grilley Olson, Atsushi Osada, Iulian Bobe, and Richard F. Riedel

TABLE OF CONTENTS

4233 NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response

A C Sandra M. Swain, Gong Tang, Heather Ann Brauer, David S. Goerlitz, Peter C. Lucas, André Robidoux, Brent T. Harris, Hanna Bandos, Yuqi Ren, Charles E. Geyer Jr, Priya Rastogi, Eleftherios P. Mamounas, and Norman Wolmark

4242 A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER⁺HER2⁻ Primary Breast Cancer

A C John F.R. Robertson, Abigail Evans, Stephan Henschen, Cliona C. Kirwan, Ali Jahan, Laura M. Kenny, J. Michael Dixon, Peter Schmid, Ashutosh Kothari, Omar Mohamed, Peter A. Fasching, Kwok-Leung Cheung, Rachel Wuerstein, Danielle Carroll, Teresa Klinowska, Justin P.O. Lindemann, Alexander MacDonald, Richard Mather, Rhiannon Maudsley, Michele Moschetta, Myria Nikolaou, Martine P. Roudier, Tinnu Sarvotham, Gaia Schiavon, Diansong Zhou, Li Zhou, and Nadia Harbeck

CLINICAL TRIALS: IMMUNOTHERAPY

4250 Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial

Bixia Tang, Zhihong Chi, Yingbo Chen, Xiufeng Liu, Di Wu, Jing Chen, Xin Song, Weifeng Wang, Lihou Dong, Haifeng Song, Hai Wu, Hui Feng, Sheng Yao, Shuikui Qin, Xiaoshi Zhang, and Jun Guo

See related commentary, p. 4171

4260 Concurrent Definitive Immunoradiotherapy for Patients with Stage III-IV Head and Neck Cancer and Cisplatin Contraindication

Jared Weiss, Siddharth Sheth, Allision M. Deal, Juneko E. Grilley Olson, Samip Patel, Trevor G. Hackman, Jeffrey M. Blumberg, Thomas J. Galloway, Shetal Patel, Adam M. Zanation, Colette J. Shen, D. Neil Hayes, Christopher Hilliard, Ranee Mehra, Karen P. McKinnon, Hsing-Hui Wang, Mark Christian Weissler, Jessica R. Bauman, Bhishamjit S. Chera, and Benjamin G. Vincent

4268 Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

Erika J. Lampert, Alexandra Zimmer, Michelle Padget, Ashley Cimino-Mathews, Jayakumar R. Nair, Yingmiao Liu, Elizabeth M. Swisher, James W. Hodge, Andrew B. Nixon, Erin Nichols, Mohammad H. Bagheri, Elliott Levy, Marc R. Radke, Stanley Lipkowitz, Christina M. Annunziata, Janis M. Taube, Seth M. Steinberg, and Jung-Min Lee

PRECISION MEDICINE AND IMAGING

4280 Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis

Kelly J. Norsworthy, Flora Mulkey, Emma C. Scott, Ashley F. Ward, Donna Przepiorka, Rosane Charlab, Sarah E. Dorff, Albert Deisseroth, Dickran Kazandjian, Rajeshwari Sridhara, Julia A. Beaver, Ann T. Farrell, R. Angelo de Claro, and Richard Pazdur

See related commentary, p. 4174

4289 The Outcome of *Ex Vivo* TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic *In Vitro* Growth Capacity between T-Cell Clones

Isabel C. Poschke, Jessica C. Hassel, Aaron Rodriguez-Ehrenfried, Katharina A.M. Lindner, Ignacio Heras-Murillo, Lena M. Appel, Johanna Lehmann, Tanja Lövgren, Stina L. Wickström, Claudia Lauenstein, Jasmin Roth, Anna-Katharina König, John B.A.G. Haanen, Joost van den Berg, Rolf Kiessling, Frank Bergmann, Michael Flossdorf, Oliver Strobel, and Rienk Offringa

See related commentary, p. 4177

4302 High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma

Wen Sun, Shi-Chao Li, Li Xu, Wei Zhong, Zhen-Guang Wang, Chu-zhi Pan, Jing Li, Guang-Zhi Jin, Na Ta, Wei Dong, Dan Liu, Hui Liu, Hong-Yang Wang, and Jin Ding

4313 The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer

Sarah McCuaig, David Barras, Elizabeth H. Mann, Matthias Friedrich, Samuel J. Bullers, Alina Janney, Lucy C. Garner, Enric Domingo, Viktor Hendrik Koelzer, Mauro Delorenzi, Sabine Tejpar, Timothy S. Maughan, Nathaniel R. West, and Fiona Powrie

4326 Prognostic Significance of Immune Cell Populations Identified by Machine Learning in Colorectal Cancer Using Routine Hematoxylin and Eosin-Stained Sections

Juha P. Väyrynen, Mai Chan Lau, Koichiro Haruki, Sara A. Väyrynen, Andressa Dias Costa, Jennifer Borowsky, Melissa Zhao, Kenji Fujiyoshi, Kota Arima, Tyler S. Twombly, Junko Kishikawa, Simeng Gu, Saina Aminmozaffari, Shanshan Shi, Yoshifumi Baba, Naohiko Akimoto, Tomotaka Ugai, Annacarolina Da Silva, Mingyang Song, Kana Wu, Andrew T. Chan, Reiko Nishihara, Charles S. Fuchs, Jeffrey A. Meyerhardt, Marios Giannakis, Shuji Ogino, and Jonathan A. Nowak

TABLE OF CONTENTS

- 4339** **Detection of Promoter DNA Methylation in Urine and Plasma Aids the Detection of Non-Small Cell Lung Cancer**
Bin Liu, Julio Ricarte Filho, Apurva Mallisetty, Cassandra Villani, Anastasia Kottorou, Kristen Rodgers, Chen Chen, Tomoaki Ito, Kyla Holmes, Nicole Gastala, Klara Valyi-Nagy, Odile David, Ron C. Gaba, Christian Ascoli, Mary Pasquinelli, Lawrence E. Feldman, Malek G. Massad, Tza-Huei Wang, Ignacio Jusue-Torres, Enrico Benedetti, Robert A. Winn, Malcolm V. Brock, James G. Herman, and Alicia Hulbert
- 4381** **Early Hepatic Lesions Display Immature Tertiary Lymphoid Structures and Show Elevated Expression of Immune Inhibitory and Immunosuppressive Molecules**
Maxime Meylan, Florent Petitprez, Laetitia Lacroix, Luca Di Tommaso, Massimo Roncalli, Antoine Bougouïn, Alexis Laurent, Giuliana Amaddeo, Daniele Sommacale, H el ene Regnault, Jonathan Derman, C ecile Charpy, Fouad Lafdil, Jean-Michel Pawlotsky, Catherine Saut es-Fridman, Wolf H. Fridman, and Julien Calderaro
- 4390** **CD8⁺ T-cell-Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas**
Joshua R. Kane, Junfei Zhao, Takashi Tsujiuchi, Brice Laffleur, V ictor A. Arrieta, Aayushi Mahajan, Ganesh Rao, Angeliki Mela, Crismita Dmello, Li Chen, Daniel Y. Zhang, Edgar Gonz alez-Buendia, Catalina Lee-Chang, Ting Xiao, Gerson Rothschild, Uttiya Basu, Craig Horbinski, Maciej S. Lesniak, Amy B. Heimberger, Raul Rabadan, Peter Canoll, and Adam M. Sonabend
- 4402** **Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type**
Jennifer X. Ji, Dawn R. Cochrane, Basile Tessier-Cloutier, Shary Yutin Chen, Germain Ho, Khyatiben V. Pathak, Isabel N. Alcazar, David Farnell, Samuel Leung, Angela Cheng, Christine Chow, Shane Colborne, Gian Luca Negri, Friedrich Kommos, Anthony Karnezis, Gregg B. Morin, Jessica N. McAlpine, C. Blake Gilks, Bernard E. Weissman, Jeffrey M. Trent, Lynn Hoang, Patrick Pirrotte, Yemin Wang, and David G. Huntsman
- 4414** **Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition**
Lucas Basler, Hubert S. Gabry s, Sabrina A. Hogan, Matea Pavic, Marta Bogowicz, Diem Vuong, Stephanie Tanadini-Lang, Robert F orster, Ken Kudura, Martin W. Huellner, Reinhard Dummer, Matthias Guckenberger, and Mitchell P. Levesque
- 4349** **AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer**
Nellie K. McDaniel, Mari Iida, Kwangok P. Nickel, Colin A. Longhurst, Samantha R. Fischbach, Tamara S. Rodems, Carlene A. Kranjac, Amber Y. Bo, Qianyun Luo, Meghan M. Gallagher, Noah B. Welke, Kaitlyn R. Mitchell, Alison E. Schulz, Jaimee C. Eckers, Rong Hu, Ravi Salgia, Seungpyo Hong, Justine Y. Bruce, Randall J. Kimple, and Deric L. Wheeler
- 4360** **Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non-Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling**
Jon Zugazagoitia, Swati Gupta, Yuting Liu, Kit Fuhrman, Scott Gettinger, Roy S. Herbst, Kurt A. Schalper, and David L. Rimm
- 4369** **Synthetic High-density Lipoprotein Nanodiscs for Personalized Immunotherapy Against Gliomas**
Lindsay Scheetz, Padma Kadiyala, Xiaoqi Sun, Sejin Son, Alireza Hassani Najafabadi, Marisa Aikins, Pedro R. Lowenstein, Anna Schwendeman, Maria G. Castro, and James J. Moon


AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

TABLE OF CONTENTS

ABOUT THE COVER

The cover shows multiplex immunofluorescence staining of a human NSCLC case (cytokeratin in green, CD3 in red, and CD56 in white). There is abundant CD56 expression in the stroma, including CD56⁺/CD3⁻ cells (NK cells) and CD56⁺/CD3⁺ cells (NKT cells). For details, see the article by Zugazagoitia and colleagues on page 4360 of this issue.



Clinical Cancer Research

26 (16)

Clin Cancer Res 2020;26:4169-4425.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/26/16>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/26/16>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.